124 related articles for article (PubMed ID: 9641003)
1. Effect of venlafaxine on the pharmacokinetics of alprazolam.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
Psychopharmacol Bull; 1998; 34(2):211-9. PubMed ID: 9641003
[TBL] [Abstract][Full Text] [Related]
2. Effect of venlafaxine on the pharmacokinetics of terfenadine.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
Psychopharmacol Bull; 1998; 34(3):383-9. PubMed ID: 9803772
[TBL] [Abstract][Full Text] [Related]
3. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
Levin GM; Nelson LA; DeVane CL; Preston SL; Eisele G; Carson SW
Psychopharmacol Bull; 2001; 35(2):62-71. PubMed ID: 12397887
[TBL] [Abstract][Full Text] [Related]
5. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
[TBL] [Abstract][Full Text] [Related]
6. Effect of venlafaxine on the pharmacokinetics of risperidone.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
J Clin Pharmacol; 1999 Mar; 39(3):297-309. PubMed ID: 10073330
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers.
Glue P; Fang A; Gandelman K; Klee B
Am J Ther; 2006; 13(5):418-22. PubMed ID: 16988537
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.
Hall J; Naranjo CA; Sproule BA; Herrmann N
J Clin Psychopharmacol; 2003 Aug; 23(4):349-57. PubMed ID: 12920410
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetically induced benzodiazepine withdrawal.
Ninan PT
Psychopharmacol Bull; 2001; 35(4):94-100. PubMed ID: 12397859
[TBL] [Abstract][Full Text] [Related]
10. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam.
Furukori H; Otani K; Yasui N; Kondo T; Kaneko S; Shimoyama R; Ohkubo T; Nagasaki T; Sugawara K
Neuropsychopharmacology; 1998 May; 18(5):364-9. PubMed ID: 9536449
[TBL] [Abstract][Full Text] [Related]
11. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
[TBL] [Abstract][Full Text] [Related]
12. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
Gex-Fabry M; Rudaz S; Balant-Gorgia AE; Brachet A; Veuthey JL; Balant LP; Bertschy G
Eur J Clin Pharmacol; 2002 Aug; 58(5):323-31. PubMed ID: 12185556
[TBL] [Abstract][Full Text] [Related]
13. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet.
Erdman K; Stypinski D; Combs M; Witt P; Stiles M; Pollock S
Pharmacotherapy; 2007 Aug; 27(8):1120-4. PubMed ID: 17655512
[TBL] [Abstract][Full Text] [Related]
14. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
Arold G; Donath F; Maurer A; Diefenbach K; Bauer S; Henneicke-von Zepelin HH; Friede M; Roots I
Planta Med; 2005 Apr; 71(4):331-7. PubMed ID: 15856409
[TBL] [Abstract][Full Text] [Related]
15. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
[TBL] [Abstract][Full Text] [Related]
16. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the interaction of lithium and alprazolam.
Evans RL; Nelson MV; Melethil S; Townsend R; Hornstra RK; Smith RB
J Clin Psychopharmacol; 1990 Oct; 10(5):355-9. PubMed ID: 2124219
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
Wright CE; Sisson TL; Fleishaker JC; Antal EJ
J Clin Pharmacol; 1997 Apr; 37(4):321-9. PubMed ID: 9115058
[TBL] [Abstract][Full Text] [Related]
20. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration.
Wang Y; Roy A; Sun L; Lau CE
Drug Metab Dispos; 1999 Aug; 27(8):855-9. PubMed ID: 10421610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
